Gday Duke. Thanks for the article. There have been several...

Gday Duke. Thanks for the article.

There have been several lately along the same lines. That is. the virus used to load the gene therapy is causing harm, as it is required to be a large amount per patient weight to carry the required dose size.
This is limiting dose size for the treatment, which in turn reduces the gene therapy efficacy.

I agree. it is positive for ANP. Perhaps the control of fibrosis (ATL1102) will allow smaller gene therapy dosr sizes to work better? Hopefully the combo study will shed some light on this.